Adage Capital Partners
NKGN

Adage Capital Partners’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Adage Capital Partners’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,350,000
Closed -$13.7M – 947
2023
Q1 		$13.7M Hold
1,350,000
– – 0.03% 539
2022
Q4 		$13.4M Hold
1,350,000
– – 0.03% 554
2022
Q3 		$13.2M Hold
1,350,000
– – 0.03% 560
2022
Q2 		$13.1M Hold
1,350,000
– – 0.03% 592
2022
Q1 		$13.1M Hold
1,350,000
– – 0.02% 615
2021
Q4 		$13.1M Hold
1,350,000
– – 0.02% 620
2021
Q3 		$13.1M Buy
+1,350,000
New +$13.2M 0.03% 615

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

Adage Capital Partners's NKGN Position: Q2 2023 in Review

Adage Capital Partners sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 1,350,000 shares — an estimated $13.7M sold.

Adage Capital Partners first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $13.7M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • Adage Capital Partners reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Adage Capital Partners sold 1,350,000 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $13.7M.
  • Adage Capital Partners first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • Adage Capital Partners's NKGen Biotech, Inc. Common Stock position peaked at $13.7M in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on Adage Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.